Float & OS126,543 / 241,002
Cash/Shr$3.15
Market Cap & EV—
Short Interest—
Cash$758,621
Est. Cash Today$-7.35 M
Off AbilityMedium
Off FreqMedium
DilutionHigh
Cash NeedHigh
Overall Offering RiskHigh
Warrant Exercise RiskHigh
Nasdaq ComplianceLow
Shares Outstanding History
Cash Position
Cash Position
The company has -8.1 months of cash left based on the quarterly cash burn of $-2.73 M and estimated current cash of $-7.35 M.
Commentary on Financial Condition
“sources of liquidity have been cash flows generated from its business operations and external financing via various instruments. As of December 31, 2024 and 2025, NewGenIvf had US$457,740 and US$758,621, respectively, in cash and cash equivalents. NewGenIvf had working” (from March 2026 filing’s Liquidity and Capital Resources) Filed At: 2026-03-31
Recent Filings
| SCHEDULE 13D/A | Form SCHEDULE 13D/A | 2026-10-06 |
| 4 | Form 4 | 2026-10-06 |
| 4 | Form 4 | 2026-10-06 |
| 6-K | Form 6-K | 2026-10-05 |
| 6-K | Form 6-K | 2026-10-01 |
| 424B4 | Form 424B4 | 2026-09-30 |
| EFFECT | Form EFFECT | 2026-09-29 |
| F-1/A | Form F-1/A | 2026-09-11 |
Insights
An at-the-market programme of up to $100,000,000 is in place.
F-1 · 2025-03-07
An at-the-market programme of up to $3,500,000 is in place.
424B3 · 2024-03-01